BridgeBio Oncology
BBOT
31 hedge funds and large institutions have $171M invested in BridgeBio Oncology in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
2% more capital invested
Capital invested by funds: $167M → $171M (+$3.69M)
0% more funds holding
Funds holding: 31 → 31 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
2.44% less ownership
Funds ownership: 89.02% → 86.59% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.24M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$138K |
| 3 |
Millennium Management
New York
|
+$134K |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$32.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$949K |
| 2 |
Walleye Trading
New York
|
-$534K |
| 3 |
CAC
Cowen and Company
New York
|
-$56.5K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$31.8K |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$24.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WP
26
Woodline Partners
San Francisco,
California
| $1.08M | – | – | – |
|
|
MCM
27
Moore Capital Management
New York
| $1.04M | – | – | – |
|
|
CAC
28
Cowen and Company
New York
| $471K | -$56.5K | -5,463 | -11% |
|
29
Geode Capital Management
Boston,
Massachusetts
| $114K | – | – | – |
|
30
UBS Group
Zurich,
Switzerland
| $219 | +$217 | +21 | New |
|
31
JP Morgan Chase
New York
| $42 | – | – | – |
|
|
32
Walleye Capital
New York
| – | -$949K | -92,864 | Closed |
|
|
33
Walleye Trading
New York
| – | -$534K | -52,236 | Closed |
|
BBOT Hedge Fund Activity: Q3 2024 in Review
31 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q3 2024, worth a combined $171M — up 2.2% from $167M a quarter earlier.
Fund positioning in BBOT was balanced in Q3 2024: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $1.24M. The largest seller was Walleye Capital, exiting entirely with an estimated $949K sold.
- 31 institutional investors held BridgeBio Oncology (BBOT) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $171M of BridgeBio Oncology stock for Q3 2024, up 2.2% quarter-over-quarter.
- 2 funds opened new BridgeBio Oncology positions in Q3 2024 and 2 closed out, a net change of 0 holders.
- The largest BridgeBio Oncology buyer in Q3 2024 was Schonfeld Strategic Advisors, an estimated $1.24M added.
- The largest BridgeBio Oncology seller in Q3 2024 was Walleye Capital, an estimated $949K sold.
Based on aggregated 13F filings for Q3 2024.